Small clinical trials have shown that psilocybin may be a potential treatment for Anorexia nervosa.

Characterised by pathological weight loss driven by restrictive feeding and excessive exercise behaviours, anorexia nervosa (AN) has one of the highest mortality rates of any psychiatric disease.

The condition is characterised by cognitive inflexibility, or rigid thinking and there is evidence that psilocybin acts by increasing flexibility.

Crucial to the use of the drug as a recognised treatment for anorexia is the need to understand how psilocybin actually works in the brain.

A study led by Dr Claire Foldi from the Monash University Biomedicine Discovery Institute and published in the journal Molecular Psychiatry, has studied psilocybin in an animal model of anorexia nervosa revealing that it improves body weight maintenance in female rats and facilitates cognitive flexibility.

Importantly, the Monash researchers found a specific mechanism within the brain by which psilocybin works to make “anorexic thinking” more pliable, opening the way for targeted therapies.

 

 

According to Dr Foldi, while selective serotonin reuptake inhibitors (antidepressants) are the leading pharmacological treatment, they are used off-label and “they do not improve clinical symptoms in underweight individuals with anorexia,” she said.

“Cognitive inflexibility is a hallmark of the condition often arising before symptoms of anorexia nervosa are obvious, and persisting after weight recovery – making this symptom a primary target for therapeutic intervention.”

SOURCE: Neuroscience News